A 72-Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease (AD) (Stage 3 AD) to Evaluate the Effect on Cognitive and Functional Impairment, Safety, and Tolerabilit

Administered By

Awarded By

Contributors

Start/End

  • March 10, 2021 - December 31, 2023